Please join us in welcoming Devanjan “Dev” Sikder, DVM, PhD to UPMC Hillman Cancer Center, effective July 1, 2024. Dr Sikder is Associate Professor in the Department of Medicine, Division of Malignant Hematology/Oncology at the University of Pittsburgh and Director of the Hematopoietic Stem Cell (HSC) Lab and Immune Monitoring and Cellular Products Laboratory (IMCPL).
Dr. Sikder will oversee the HSC Lab and IMCPL, working to address the day-to-day activities, budget, staffing, and quality of these labs, and will partner with UPMC Hillman Cancer Center leadership to manage and bring in new projects, trials, and medical coverage for these facilities.
He is joining us from Memorial Sloan Kettering (MSK) Cancer Center, where he was Associate Director of Quality & Operations of their Cell Therapy and Cell Engineering Facility, which develops CAR-Ts, TCRs, NK cells, iPSCs, and gene-edited therapies for hemoglobinopathies. Dr. Sikder is experienced with organizational quality assessments and accreditation, including as a member of MSK CTS Cell Therapy Quality Assessment Committee, leading MSK’s FACT accreditation for immune effector cell therapy manufacturing, the FACT & JACIE certified inspector for GMP and Clinical Quality Management, and as Director, Quality Compliance & Technical Operations at Vigene. Prior to these positions, he was assistant professor at Sanford Burnham Medical Research Institute and UT Southwestern Medical School.
Dr. Sikder earned his DVM and PhD in India. He completed his post doc in internal medicine at UT Southwestern Medical Center with Noble Laureate Thomas Sudhof.
